BioCentury | Jul 12, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

...inhibiting CTU2 or ELP3 could help treat drug-resistant BRAF-mutant melanoma University of Liège Distillery Therapeutics Elongator acetyltransferase complex subunit 3 (ELP3)...
BioCentury | Jun 28, 2018
Distillery Therapeutics


...Phase II testing for BRAF mutation-positive thyroid cancer. TARGET/MARKER/PATHWAY: BRAF; cytosolic thiouridylase subunit 2 (CTU2); elongator acetyltransferase complex subunit 3 (ELP3)...
Items per page:
1 - 2 of 2